SCHEMBL10234979

SCHEMBL10234979

CCc1cnn2cc(-c3ccc(F)nc3)ccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 4/20 0.38
JAK3 P52333 4/20 0.38
JAK2 O60674 2/20 0.38
TYK2 P29597 1/20 0.38
KCNH2 Q12809 1/20 0.38
RET P07949 2/20 0.37
KDR P35968 1/20 0.37
GSK3A P49840 1/20 0.37
RPS6KA3 P51812 1/20 0.37
LIMK1 P53667 1/20 0.37
MAP2K1 Q02750 1/20 0.37
DYRK1A Q13627 1/20 0.37
MAPK14 Q16539 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
ALK Q9UM73 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
CYP2A6 P11509 3/20 0.36
CYP2B6 P20813 3/20 0.36
CYP2E1 P05181 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10233666 0.83 ACVR2A (0.32) KCNH2RETDYRK1AMAPTGRIN2B
SCHEMBL10234136 0.82 JAK1 (0.40) JAK1JAK3JAK2TYK2KCNH2
SCHEMBL10235432 0.78 JAK1 (0.39) JAK1JAK3JAK2TYK2KCNH2
SCHEMBL10233668 0.78 PIK3CG (0.40) JAK1JAK3JAK2TYK2KCNH2
SCHEMBL10182956 0.77 JAK1 (0.38) JAK1JAK3JAK2TYK2KCNH2
SCHEMBL23133667 0.77 KCNH2 (0.37) KCNH2MAPK14MAPTGRIN2B
SCHEMBL10235403 0.74 JAK1 (0.37) JAK1JAK3RETKDRMAPK14
SCHEMBL10233441 0.72 ACVR2A (0.53) JAK1JAK3JAK2TYK2
SCHEMBL23425908 0.72 EPHB3 (0.42) MAPK14PDE2A
SCHEMBL25099101 0.70 EPHB3 (0.43) KCNH2MAPTCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF JAK1 941/4885JAK3 853/4885JAK2 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.